The Phase II clinical trial of myopia control treatment has enrolled a total of 112 participants.

Approximately 80% of the subjects have successfully completed one year of the trial.

The last subject is expected to complete the study medication administration by December 31, 2026, marking the completion of the treatment phase.

The trial is progressing smoothly and in line with expectations.